Cadonilimab Combined With RT in LACC Patients Ineligible for CCRT

Inclusion Criteria: 1. Female, age ≥18 years. 2. Histologically confirmed cervical squamous cell carcinoma or adenosquamous carcinoma. 3. FIGO 2018 stage IB3-IVA, or medically inoperable disease requiring definitive radiotherapy. 4. ECOG performance status 0-2, life expectancy ≥6 months. 5. Presence of at least one absolute or relative contraindication to concurrent cisplatin based chemotherapy, defined as: * Age ≥70 years; OR * Renal impairment: serum creatinine \>1.5 × upper limit of normal (ULN) or calculated creatinine clearance (CrCl) \<50 mL/min (Cockcroft Gault); OR * Cardiac dysfunction: New York Heart Association class ≥II; OR * Prior allergic reaction to platinum agents; OR * Patient refusal of chemotherapy after thorough counselling. 6. Adequate organ function: * Total bilirubin ≤1.5 × ULN (≤3 × ULN for Gilbert's syndrome) * AST and ALT ≤2.5 × ULN 7. Willing and able to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures. Exclusion Criteria: 1. Prior or concurrent invasive malignancy unless disease free for ≥5 years (exceptions: non melanoma skin cancer, cured in situ carcinoma). 2. No histological confirmation of cervical cancer. 3. Prior exposure to anti PD 1/PD L1, anti CTLA 4, or other immune checkpoint inhibitors. 4. Congenital or acquired immunodeficiency (e.g., HIV infection). 5. Active hepatitis B (HBsAg positive with detectable HBV DNA) or hepatitis C (HCV RNA positive). 6. Pregnancy or lactation (negative serum/urine β hCG required for premenopausal women). 7. Severe uncontrolled comorbidities precluding safe radiotherapy: * Unstable angina, myocardial infarction, or congestive heart failure requiring hospitalisation within 6 months * Acute bacterial or systemic fungal infection * Chronic obstructive pulmonary disease exacerbation requiring hospitalisation * Active connective tissue disease (e.g., systemic lupus erythematosus, scleroderma) 8. Psychiatric illness or social condition that would limit study compliance. 9. Inability to understand the study purpose or refusal to sign informed consent. 10. Any other condition that, in the investigator's judgment, makes the patient unsuitable for study participation.